🇺🇸 FDA
Patent

US 8431124

Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 8431124 (Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)) held by HALOZYME, INC. expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HALOZYME, INC.
Grant date
Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K38/00, A61K38/47, A61K39/395